BlackThorn Raises $76m To Personalize Medicines For Neurobehavioral Disorders

BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.

MR  image of Human brain
BlackThorn uses AI and machine learning to find neurobehavioral drug targets. • Source: Shutterstock

BlackThorn Therapeutics Inc. put its $54m in series A venture capital funding to work, emerging with a refined artificial intelligence and machine learning (AI/ML) platform for the development of personalized medicines to treat neurobehavioral disorders and with a drug in the clinic. On 13 June, the company said it has raised $76m in series B cash to advance its lead drug candidate and take a second program into human studies.

San Francisco-based BlackThorn launched in October 2016 with a $40m series A round that was expanded a few months later...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.